Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 19/20 | 0.41 |
| ▸ | EGFR | P00533 | 7/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | FECH | P22830 | 1/20 | 0.40 |
| ▸ | MYH14 | Q7Z406 | 1/20 | 0.40 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30613042 | 0.92 | ERBB2 (0.39) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL26579583 | 0.90 | ERBB2 (0.44) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL26128354 | 0.87 | GAA (0.47) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL29888185 | 0.86 | ERBB2 (0.43) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL22525244 | 0.86 | ERBB2 (0.43) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL26580265 | 0.83 | ERBB2 (0.42) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL31325447 | 0.83 | ERBB2 (0.51) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL26579227 | 0.83 | ERBB2 (0.51) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL31325449 | 0.83 | ERBB2 (0.51) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL29414877 | 0.81 | ERBB2 (0.48) | ERBB2EGFRNQO2FECHMYH14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4506343-A1 | HETEROARYL DERIVATIVE AND USE THEREOF | Voronoi Inc. (KR) | 2025-02-12 | — | — | EP | disclosed |
| US-20240383923-A1 | HETEROARYL DERIVATIVE AND USE THEREOF | VORONOI INC. (KR) | 2024-11-21 | — | — | US | disclosed |
| CN-118946557-A | Heteroaryl derivatives and uses thereof | 株式会社沃若诺伊 | 2024-11-12 | — | — | CN | disclosed |
| WO-2024048809-A1 | HETEROARYL DERIVATIVE CONTAINING N, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 보로노이 주식회사 | 2024-03-07 | — | — | WO | disclosed |
| WO-2023195773-A1 | HETEROARYL DERIVATIVE AND USE THEREOF | 보로노이 주식회사 | 2023-10-12 | — | — | WO | disclosed |
| WO-2023195773-A1 | HETEROARYL DERIVATIVE AND USE THEREOF | 보로노이 주식회사 | 2023-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383923-A1 | HETEROARYL DERIVATIVE AND USE THEREOF | ERBB2, ERBB3, EGFR | ERBB2 1/4885EGFR 3/4885NQO2 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.